19 October-1 December 2020
The 51st Union World Conference On Lung Health
REGISTER NOW

Sessions

All Sessions
keyboard_arrow_down
keyboard_arrow_down Show filters keyboard_arrow_up Hide filters
  • All Tracks
  • Community Connect
  • Channel 1
  • Channel 2
  • Channel 3
  • Channel 4
  • Channel 5
  • Channel 6
  • Channel 7
  • E-posters
  • Workshops
E-posters
EPTBS-TBScience 2020 - E-posters - Displayed All Conference Days
event_note
Loading...
query_builder 10:00 - 11:00 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel E-poster session
mic English
EPTBS-TBScience 2020 - E-posters - Displayed All Conference Days
*Please scroll down for more information*
All TBScience 2020 E-posters will be displayed from 10 am Central European Summer Time (CEST), on Wednesday, 21 October for the duration of the conference and beyond

EP-TBS-01-Increased neutrophil count and decreased neutrophil CD15 expression correlate with TB disease severity and treatment response
Lerato Ndlovu

EP-TBS-02-Genome-wide identification of Mycobacterium tuberculosis genetic markers associated with the history of BCG vaccination
Kamela Charmaine S. Ng

EP-TBS-03-Characterization of regulatory B-cells for tuberculosis management
Irene Latorre

EP-TBS-04-Different antimycobacterial activity of alveolar macrophages in various lung legions of tuberculosis patients
Sergey Skornyakov

EP-TBS-05-Plasma mediators of phagocytosis in tuberculosis patients during anti-TB treatment and zinc supplementation
Victory Edem

EP-TBS-06-Discerning divergent tuberculosis endotypes: A meta-analysis of individual patient data
Andrew DiNardo

EP-TBS-07-Plasma Interferon (IFN)-g Inducible Protein 10 (IP-10) levels but not the QuantiFERON Gold plus assay correlate with disease severity and paradoxical reactions in extrapulmonary tuberculosis
Isabelle Suarez

EP-TBS-08-Host immune factors related to non-multidrug resistant tuberculosis with treatment history in Vietnam
Naoto Keicho

EP-TBS-09-Risk factors for the development of tuberculosis in children with chronic non-specific lung diseases.
Sofya Nakonechnaya

EP-TBS-10-Polyfunctional T-cells and IL-2 production decrease during pregnancy in women with latent TB infection
Jyoti Mathad

EP-TBS-11-Neutrophils Contribute to Tuberculosis-linked Inflammation and lung pathology
Caleb Nwongbouwoh Muefong

EP-TBS-12-Association of neutrophil-derived inflammatory mediator levels with lung pathology in active tuberculosis at diagnosis
Caleb Nwongbouwoh Muefong

EP-TBS-13-Characterising the BCG-induced antibody response for antigen discovery
Rachel Tanner

EP-TBS-14-ESAT-6 / CFP-10-stimulated metabolic activity of pleural fluid cells if cured tuberculosis or TB / HIV
Sergey Skornyakov

EP-TBS-15-Blood-Based Biomarkers of Tuberculosis in Children Integrating Metabolomic and Transcriptomic Data
Jeffrey A Tornheim

EP-TBS-16-Identification of TGF-β1 in pleural tuberculosis: the possible role in fibrosis
Silvio Renan Pinheiro Victor de Araújo

EP-TBS-17-Analysis of serum microRNAs as pulmonary tuberculosis biomarkers
JaeIn Jung

EP-TBS-18-Up-regulated programmed death protein 1 expression on CD4 T cells in patients with MDR-TB  associated with lung lesion and mycobacterial load
Qi Tan

EP-TBS-19-Malnutrition affects levels of vascular endothelial growth factor levels among children and adolescents with pulmonary tuberculosis?
Caio Pluvier Duarte Costa

EP-TBS-20-Towards identification of protein markers of Mycobacterium tuberculosis H37Rv extracellular vesicles (EV)
MEHALENE JAYARAM

EP-TBS-21-Increased frequency of CD39+ regulatory T cells in the pleural fluid of patients with Tuberculosisin comparison to other exudative causes
Ana Paula Santos

EP-TBS-22-Longitudinal analysis of M. tuberculosis-specific T cell responses demonstrates dynamic T cell responses to ESAT-6 and CFP-10 during pregnancy independently of mitogen responses.
Aparajita Saha

EP-TBS-23-Serum Cytokine Profile as Biomarker for Multi-drug Resistant Tuberculosis
Alahaman Nana Boakye

EP-TBS-24-Reanalysis and validation of Tuberculosis genes signature in blood and pleural fluid from patients with exudative pleural effusion
Raquel da Silva Corrêa

EP-TBS-25-TimBre, Cough based screening of Pulmonary Tuberculosis using Machine Learning that is Explainable and Interpretable
Rahul Pathri

EP-TBS-26-HbA1C as prognostic factor in PTB
Sarang Patil

EP-TBS-27-Better intradermal delivery for bacille Calmette-Guérin (BCG) vaccine by microneedles in healthy adults of S. Korea
Hyejon Lee

EP-TBS-28-MULTIPLEX BIOMARKER ASSAY FOR DETECTION OF MYCOBACTERIUM TUBERCULOSIS
Puneet Gupta

EP-TBS-29-Role of the chemokine receptor CXCR3 in the recruitment and retention of lung resident memory T cells following a pulmonary TB vaccine. 
Warwick Britton

EP-TBS-31-Benefit of Quantiferon-TB Gold plus in incidence of TB disease in Heath care workers of Central Chest Institute of Thailand
piamlarp sangsayunh

EP-TBS-32-The blood monocyte/lymphocyte, neutrophil/lymphocyte and platelet/lymphocyte ratios in children with pulmonary tuberculosis
Larissa Gorbach

EP-TBS-33-Pulmonary tuberculosis patients have an anaerobe-enriched microbiota associated with a pro-inflammatory peripheral host immune phenotype
Charissa Naidoo

EP-TBS-34-The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on rifampicin resistant and multidrug resistant tuberculosis in India and China
Chathika Weerasuriya

EP-TBS-36-Novel, culture-free, same-day TB diagnosis with ultrasensitive ELISA
Rikiya Takeuchi

EP-TBS-37-Tuberculosis screening in point-of-care settings: Proof-of-concept for a fast and easy sample-to-answer qPCR-based protocol
Alexandre Dias Tavares Costa

EP-TBS-38-Diagnostic accuracy of three urine lipoarabinomannan tuberculosis assays in HIV-negative outpatients
Tobias Broger

EP-TBS-39-To Study The Presence Of Live Mycobacterium Tuberculosis In Resected Lung Specimens Of Patients Undergoing Lung resection Surgery For Post-Tuberculosis Sequelae
Pallavi Purwar

EP-TBS-40-What can tuberculosis prevalence surveys tell us about the duration of asymptomatic bacteriologically-positive disease?
Chu-Chang Ku

EP-TBS-41-An RNA signature for tuberculosis risk in pregnant women: a prospective cohort study from India
Jyoti Mathad

EP-TBS-42-Analysis of mycobacterial trans-renal DNA for the diagnosis of Tuberculous Meningitis in adults.
Manisha Dass

EP-TBS-43-Developing a tool to identify and screen Latent Tuberculosis Infection (LTBI) with likelihood of progression to active Tuberculosis (ATB)
Prashant Singh

EP-TBS-44-QuantiFERON TB plus-negative results in clinically diagnosed paediatric tuberculosis: immune suppression or misdiagnosis?
Gloria Ivy Mensah

EP-TBS-45-Evaluation of a blood-based antigen test for tuberculosis in HIV-exposed children younger than 5 years
Tony Hu

EP-TBS-46-Adverse drug reactions in MDR TB Patients on ATT
Sarang Patil

EP-TBS-47-Species and Drug Susceptibility profile of Non-tuberculous Mycobacteria isolated from presumptive TB cases
PRIYA RAJENDRAN

EP-TBS-48-MAMA-PCR assay for the detection of point mutations associated with drug resistance in Mycobacterium tuberculosis clinical isolates
Raquel Muñiz-Salazar

EP-TBS-49-Genomic diversity in Mycobacterium tuberculosis from human lung resections reveals a high degree of multiclonal infections in a high-burden MDR-TB setting
Miguel Moreno-Molina

EP-TBS-50-Pathogen genome sequencing to guide treatment regimen designs for multidrug-resistant tuberculosis
Hans-Peter Grobbel

EP-TBS-51-An evolutionary functional genomics approach identifies novel candidate regions involved in isoniazid resistance in Mycobacterium tuberculosis
Victoria Furió

EP-TBS-52-Antibiotic Resistance Profile Determination Using Whole Genome Sequencing
Ryan Howard

EP-TBS-53-Rapid genomic drug resistance prediction from clinical Mycobacterium tuberculosis specimens using amplicon based deep sequencing based on Deeplex-MycTB
Stefan Niemann

EP-TBS-54-Multi-resistant tuberculosis and HIV infection in Kinshasa: 2011-2018. DRC “Epidemiological, clinical and therapeutic aspects”
Nicole ANSHAMBI

EP-TBS-55-Long Read DNA Sequencing of XDR/MDR Tuberculosis Samples to Investigate Factors Leading to Resistance and Virulence
Michael Harris

EP-TBS-56-Genome-wide detection of epistasis in antibiotic resistant M. tuberculosis
Anna Green

EP-TBS-57-Population structure, biogeography and transmissibility of Mycobacterium tuberculosis
Luca Freschi

EP-TBS-58-Safety and Efficacy of an MDR-TB All-oral Short-course Regimen in China: An Preliminary Analysis of the MDR-Chi clinical trial
Liang Fu

EP-TBS-59-Drug exposure and minimum inhibitory concentration predict pulmonary tuberculosis treatment response
Xubin Zheng

EP-TBS-60-A novel therapeutic vaccine against multi-drug resistant tuberculosis by T cell-immunity in phase 1 clinical trial.
Masaji Okada

EP-TBS-61-Improving the safety of TB therapy with novel diagnostic biomarkers of liver toxicity – a study in UK and Ugandan patients
Derek Sloan

EP-TBS-62-Tuberculosis meningitis mouse model
Tuhina Gupta

EP-TBS-63-Pharmacokinetics of the three-drug fixed-dose dispersible tablet in children
Aziza Pakhlavonova

EP-TBS-64-Does BCG Vaccination protect against infection with Mycobacterium tuberculosis in Vietnamese schoolchildren?
Puck Pelzer

EP-TBS-65-Time to positivity as a surrogate biomarker of time to culture conversion
Belén P. Solans

EP-TBS-66-Use of the contact management register to identify those with Active and Latent TB, Kenya, Jan-March 2020
RHODA POLA

EP-TBS-67-Predicting Efficacy Outcome of Nine Tuberculosis Drugs in Phase 2a First-in-patients Studies
Nan Zhang

EP-TBS-69-Predicting optimal treatment durations for tuberculosis patients: a risk stratification algorithm and clinical simulation tool
Marjorie Imperial

EP-TBS-70-Adverse Drug Reactions in MDR TB Patients on Category IV Regimen in Western Odisha
SUMAN KUMAR JAGATY

EP-TBS-71-The effect of antiretroviral therapy and preventive tuberculosis therapy with anti-TB drugs on the duration of TB remission in HIV-infected patients
Igor Medvinskiy

EP-TBS-72-A Urine Colorimetric Assay for Levofloxacin Concentrations and Optimized Regimen Development
Prakruti Rao

EP-TBS-73-Development and Application of an Integrated Biomarker - Clinical Endpoint Tool for Late Stage TB Regimen Development and Clinical Trial Design
Marjorie Imperial

EP-TBS-74-Leveraging Neural Networks and Imaging Experts in Loops for Automated Tuberculosis Screening Using Chest Radiographs in Population Screening Programs to ensure efficient workflows.
Amit Kharat

EP-TBS-75-A model for the integration of traditional medicine into conventional medicine for the treatment of Tuberculosis (TB) in Zimbabwe
Winnet Enerita Chipato

EP-TBS-76-Point-of-Care Saliva Assay for Levofloxacin Concentrations and Personalized Dosing in Patients with Multidrug-Resistant Tuberculosis in Tanzania
Sagal Mohamed

EP-TBS-77-PBPK Model Informed Prediction to Evaluate the Effect of Renal Impairment and OCT genotypes on the Ethambutol Disposition
Yumi Park

EP-TBS-78-Development of Population Pharmacokinetic Model of the First-line anti-TB drugs in Korean patients with TB for Therapeutic Drug Monitoring Guided Dose Adjustment
Yumi Park

EP-TBS-79-Model Informed Personalized Dosing Algorithm Development for TB Therapy in Center for Personalized Precision Medicine (cPMTb)
Yumi Park

EP-TBS-80-Classifying adherence trajectories: an innovative tool for regimen development
Stephanie Law

EP-TBS-81-Predicting pretomanid penetration into patient lesions of tuberculosis
Jacqueline Ernest

EP-TBS-82-Rifapentine pharmacokinetics and pharmacodynamics: murine and human models to identify optimal dosing for treatment of latent M. tuberculosis infection
Jacqueline Ernest

EP-TBS-83-SLCO1B1 and SLC10A1 polymorphism and plasma rifampin concentrations in patients with co-morbidity tuberculosis-diabetes mellitus in Baja California, Mexico
Ricardo Perea-Jacobo

EP-TBS-84-Individual-Level Data Meta-Analysis of Adverse Events from Clinical Trials of Drug Sensitive Tuberculosis Treatment Regimens
Leah Jarlsberg

EP-TBS-85-G-clamp-inspired ligands and their effects on G-quadruplexes from Mycobacterium tuberculosis
Egor Shitikov

EP-TBS-86-Prediction of early bacterial activity (EBA) of bedaquiline in tuberculosis
Federico Romano

Loading...
Channel 7
TBS1A-Role of innate and adaptive immunity in TB and evaluation of immune correlates in pre-clinical and clinical studies: plenary session
event_note
Loading...
query_builder 15:00 - 16:22 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel TBScience session
mic English
TBS1A-Role of innate and adaptive immunity in TB and evaluation of immune correlates in pre-clinical and clinical studies: plenary session
*Please scroll down for more information*
In this session recent insights into the host immune response to M. tuberculosis infection will be discussed. The results from a first tuberculosis (TB) biomarker guided clinical trial will be reported and discussed in the context of TB risk and targeted interventions. The role of innate trained immunity will next be reviewed and discussed, including in the context of BCG vaccination. The emerging role of antibodies in TB will be reviewed as well. The three keynote presentations will be followed by the selected abstract presentations and close with an open panel discussion.


15:00 - 15:03: Introductory note

Tom H. M. Ottenhoff

15:03 - 15:23: TB biomarkers and first results of the CORTIS trial

Thomas Scriba

15:23 - 15:43: BCG vaccination, trained immunity, TB and COVID-19

Reinout van Crevel

15:43 - 16:03: Antibodies as a bridge between the innate and adaptive immune system

Galit Alter

16:03 - 16:22: Live Q&A


Loading...
Channel 7
TBS1B-Role of innate and adaptive immunity in TB and evaluation of immune correlates in pre-clinical and clinical studies: oral abstract presentations
event_note
Loading...
query_builder 16:30 - 17:12 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel TBScience session
mic English
TBS1B-Role of innate and adaptive immunity in TB and evaluation of immune correlates in pre-clinical and clinical studies: oral abstract presentations
*Please scroll down for more information*
In this session recent insights into the host immune response to M. tuberculosis infection will be discussed. The results from a first tuberculosis (TB) biomarker guided clinical trial will be reported and discussed in the context of TB risk and targeted interventions. The role of innate trained immunity will next be reviewed and discussed, including in the context of BCG vaccination. The emerging role of antibodies in TB will be reviewed as well. The three keynote presentations will be followed by the selected abstract presentations and close with an open panel discussion.

16:30 - 16:32: Session introduction


16:32 - 16:40: TBS-OA-01-Inflammatory markers in the cerebrospinal fluid linked to mortality in tuberculous meningitis

Valerie A.C.M. Koeken

16:40 - 16:48: TBS-OA-02-Vaccination with intravenous BCG protects SIV+ macaques from tuberculosis.

Erica Larson

16:48 - 16:56: TBS-OA-03-A pilot study on plasma metabolomic characterization of patents with MDR-TB

Qi Tan

16:56 - 17:04: TBS-OA-04-A 22-gene transcriptomic model predicting individual therapy durations in multidrug-resistant tuberculosis

Jan Heyckendorf

17:04 - 17:12: Live Q&A


Loading...
Channel 7
TBS1C-Correlates of risk versus protection: panel discussion
event_note
Loading...
query_builder 17:20 - 18:05 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel TBScience session
mic English
TBS1C-Correlates of risk versus protection: panel discussion
*Please scroll down for more information*
In this session recent insights into the host immune response to M. tuberculosis infection will be discussed. The results from a first tuberculosis (TB) biomarker guided clinical trial will be reported and discussed in the context of TB risk and targeted interventions. The role of innate trained immunity will next be reviewed and discussed, including in the context of BCG vaccination. The emerging role of antibodies in TB will be reviewed as well. The three keynote presentations will be followed by the selected abstract presentations and close with an open panel discussion.


17:20 - 17:45: Panel discussion

Thomas Scriba
Reinout van Crevel
Galit Alter
Ann Ginsberg

17:45 - 18:05: Live Q&A

Thomas Scriba
Reinout van Crevel
Galit Alter
Ann Ginsberg

Loading...
E-posters
EPTBS-TBScience 2020 - E-posters - Displayed All Conference Days
event_note
Loading...
query_builder 10:00 - 11:00 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel E-poster session
mic English
EPTBS-TBScience 2020 - E-posters - Displayed All Conference Days
*Please scroll down for more information*
All TBScience 2020 E-posters will be displayed from 10 am Central European Summer Time (CEST), on Wednesday, 21 October for the duration of the conference and beyond

EP-TBS-01-Increased neutrophil count and decreased neutrophil CD15 expression correlate with TB disease severity and treatment response
Lerato Ndlovu

EP-TBS-02-Genome-wide identification of Mycobacterium tuberculosis genetic markers associated with the history of BCG vaccination
Kamela Charmaine S. Ng

EP-TBS-03-Characterization of regulatory B-cells for tuberculosis management
Irene Latorre

EP-TBS-04-Different antimycobacterial activity of alveolar macrophages in various lung legions of tuberculosis patients
Sergey Skornyakov

EP-TBS-05-Plasma mediators of phagocytosis in tuberculosis patients during anti-TB treatment and zinc supplementation
Victory Edem

EP-TBS-06-Discerning divergent tuberculosis endotypes: A meta-analysis of individual patient data
Andrew DiNardo

EP-TBS-07-Plasma Interferon (IFN)-g Inducible Protein 10 (IP-10) levels but not the QuantiFERON Gold plus assay correlate with disease severity and paradoxical reactions in extrapulmonary tuberculosis
Isabelle Suarez

EP-TBS-08-Host immune factors related to non-multidrug resistant tuberculosis with treatment history in Vietnam
Naoto Keicho

EP-TBS-09-Risk factors for the development of tuberculosis in children with chronic non-specific lung diseases.
Sofya Nakonechnaya

EP-TBS-10-Polyfunctional T-cells and IL-2 production decrease during pregnancy in women with latent TB infection
Jyoti Mathad

EP-TBS-11-Neutrophils Contribute to Tuberculosis-linked Inflammation and lung pathology
Caleb Nwongbouwoh Muefong

EP-TBS-12-Association of neutrophil-derived inflammatory mediator levels with lung pathology in active tuberculosis at diagnosis
Caleb Nwongbouwoh Muefong

EP-TBS-13-Characterising the BCG-induced antibody response for antigen discovery
Rachel Tanner

EP-TBS-14-ESAT-6 / CFP-10-stimulated metabolic activity of pleural fluid cells if cured tuberculosis or TB / HIV
Sergey Skornyakov

EP-TBS-15-Blood-Based Biomarkers of Tuberculosis in Children Integrating Metabolomic and Transcriptomic Data
Jeffrey A Tornheim

EP-TBS-16-Identification of TGF-β1 in pleural tuberculosis: the possible role in fibrosis
Silvio Renan Pinheiro Victor de Araújo

EP-TBS-17-Analysis of serum microRNAs as pulmonary tuberculosis biomarkers
JaeIn Jung

EP-TBS-18-Up-regulated programmed death protein 1 expression on CD4 T cells in patients with MDR-TB  associated with lung lesion and mycobacterial load
Qi Tan

EP-TBS-19-Malnutrition affects levels of vascular endothelial growth factor levels among children and adolescents with pulmonary tuberculosis?
Caio Pluvier Duarte Costa

EP-TBS-20-Towards identification of protein markers of Mycobacterium tuberculosis H37Rv extracellular vesicles (EV)
MEHALENE JAYARAM

EP-TBS-21-Increased frequency of CD39+ regulatory T cells in the pleural fluid of patients with Tuberculosisin comparison to other exudative causes
Ana Paula Santos

EP-TBS-22-Longitudinal analysis of M. tuberculosis-specific T cell responses demonstrates dynamic T cell responses to ESAT-6 and CFP-10 during pregnancy independently of mitogen responses.
Aparajita Saha

EP-TBS-23-Serum Cytokine Profile as Biomarker for Multi-drug Resistant Tuberculosis
Alahaman Nana Boakye

EP-TBS-24-Reanalysis and validation of Tuberculosis genes signature in blood and pleural fluid from patients with exudative pleural effusion
Raquel da Silva Corrêa

EP-TBS-25-TimBre, Cough based screening of Pulmonary Tuberculosis using Machine Learning that is Explainable and Interpretable
Rahul Pathri

EP-TBS-26-HbA1C as prognostic factor in PTB
Sarang Patil

EP-TBS-27-Better intradermal delivery for bacille Calmette-Guérin (BCG) vaccine by microneedles in healthy adults of S. Korea
Hyejon Lee

EP-TBS-28-MULTIPLEX BIOMARKER ASSAY FOR DETECTION OF MYCOBACTERIUM TUBERCULOSIS
Puneet Gupta

EP-TBS-29-Role of the chemokine receptor CXCR3 in the recruitment and retention of lung resident memory T cells following a pulmonary TB vaccine. 
Warwick Britton

EP-TBS-31-Benefit of Quantiferon-TB Gold plus in incidence of TB disease in Heath care workers of Central Chest Institute of Thailand
piamlarp sangsayunh

EP-TBS-32-The blood monocyte/lymphocyte, neutrophil/lymphocyte and platelet/lymphocyte ratios in children with pulmonary tuberculosis
Larissa Gorbach

EP-TBS-33-Pulmonary tuberculosis patients have an anaerobe-enriched microbiota associated with a pro-inflammatory peripheral host immune phenotype
Charissa Naidoo

EP-TBS-34-The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on rifampicin resistant and multidrug resistant tuberculosis in India and China
Chathika Weerasuriya

EP-TBS-36-Novel, culture-free, same-day TB diagnosis with ultrasensitive ELISA
Rikiya Takeuchi

EP-TBS-37-Tuberculosis screening in point-of-care settings: Proof-of-concept for a fast and easy sample-to-answer qPCR-based protocol
Alexandre Dias Tavares Costa

EP-TBS-38-Diagnostic accuracy of three urine lipoarabinomannan tuberculosis assays in HIV-negative outpatients
Tobias Broger

EP-TBS-39-To Study The Presence Of Live Mycobacterium Tuberculosis In Resected Lung Specimens Of Patients Undergoing Lung resection Surgery For Post-Tuberculosis Sequelae
Pallavi Purwar

EP-TBS-40-What can tuberculosis prevalence surveys tell us about the duration of asymptomatic bacteriologically-positive disease?
Chu-Chang Ku

EP-TBS-41-An RNA signature for tuberculosis risk in pregnant women: a prospective cohort study from India
Jyoti Mathad

EP-TBS-42-Analysis of mycobacterial trans-renal DNA for the diagnosis of Tuberculous Meningitis in adults.
Manisha Dass

EP-TBS-43-Developing a tool to identify and screen Latent Tuberculosis Infection (LTBI) with likelihood of progression to active Tuberculosis (ATB)
Prashant Singh

EP-TBS-44-QuantiFERON TB plus-negative results in clinically diagnosed paediatric tuberculosis: immune suppression or misdiagnosis?
Gloria Ivy Mensah

EP-TBS-45-Evaluation of a blood-based antigen test for tuberculosis in HIV-exposed children younger than 5 years
Tony Hu

EP-TBS-46-Adverse drug reactions in MDR TB Patients on ATT
Sarang Patil

EP-TBS-47-Species and Drug Susceptibility profile of Non-tuberculous Mycobacteria isolated from presumptive TB cases
PRIYA RAJENDRAN

EP-TBS-48-MAMA-PCR assay for the detection of point mutations associated with drug resistance in Mycobacterium tuberculosis clinical isolates
Raquel Muñiz-Salazar

EP-TBS-49-Genomic diversity in Mycobacterium tuberculosis from human lung resections reveals a high degree of multiclonal infections in a high-burden MDR-TB setting
Miguel Moreno-Molina

EP-TBS-50-Pathogen genome sequencing to guide treatment regimen designs for multidrug-resistant tuberculosis
Hans-Peter Grobbel

EP-TBS-51-An evolutionary functional genomics approach identifies novel candidate regions involved in isoniazid resistance in Mycobacterium tuberculosis
Victoria Furió

EP-TBS-52-Antibiotic Resistance Profile Determination Using Whole Genome Sequencing
Ryan Howard

EP-TBS-53-Rapid genomic drug resistance prediction from clinical Mycobacterium tuberculosis specimens using amplicon based deep sequencing based on Deeplex-MycTB
Stefan Niemann

EP-TBS-54-Multi-resistant tuberculosis and HIV infection in Kinshasa: 2011-2018. DRC “Epidemiological, clinical and therapeutic aspects”
Nicole ANSHAMBI

EP-TBS-55-Long Read DNA Sequencing of XDR/MDR Tuberculosis Samples to Investigate Factors Leading to Resistance and Virulence
Michael Harris

EP-TBS-56-Genome-wide detection of epistasis in antibiotic resistant M. tuberculosis
Anna Green

EP-TBS-57-Population structure, biogeography and transmissibility of Mycobacterium tuberculosis
Luca Freschi

EP-TBS-58-Safety and Efficacy of an MDR-TB All-oral Short-course Regimen in China: An Preliminary Analysis of the MDR-Chi clinical trial
Liang Fu

EP-TBS-59-Drug exposure and minimum inhibitory concentration predict pulmonary tuberculosis treatment response
Xubin Zheng

EP-TBS-60-A novel therapeutic vaccine against multi-drug resistant tuberculosis by T cell-immunity in phase 1 clinical trial.
Masaji Okada

EP-TBS-61-Improving the safety of TB therapy with novel diagnostic biomarkers of liver toxicity – a study in UK and Ugandan patients
Derek Sloan

EP-TBS-62-Tuberculosis meningitis mouse model
Tuhina Gupta

EP-TBS-63-Pharmacokinetics of the three-drug fixed-dose dispersible tablet in children
Aziza Pakhlavonova

EP-TBS-64-Does BCG Vaccination protect against infection with Mycobacterium tuberculosis in Vietnamese schoolchildren?
Puck Pelzer

EP-TBS-65-Time to positivity as a surrogate biomarker of time to culture conversion
Belén P. Solans

EP-TBS-66-Use of the contact management register to identify those with Active and Latent TB, Kenya, Jan-March 2020
RHODA POLA

EP-TBS-67-Predicting Efficacy Outcome of Nine Tuberculosis Drugs in Phase 2a First-in-patients Studies
Nan Zhang

EP-TBS-69-Predicting optimal treatment durations for tuberculosis patients: a risk stratification algorithm and clinical simulation tool
Marjorie Imperial

EP-TBS-70-Adverse Drug Reactions in MDR TB Patients on Category IV Regimen in Western Odisha
SUMAN KUMAR JAGATY

EP-TBS-71-The effect of antiretroviral therapy and preventive tuberculosis therapy with anti-TB drugs on the duration of TB remission in HIV-infected patients
Igor Medvinskiy

EP-TBS-72-A Urine Colorimetric Assay for Levofloxacin Concentrations and Optimized Regimen Development
Prakruti Rao

EP-TBS-73-Development and Application of an Integrated Biomarker - Clinical Endpoint Tool for Late Stage TB Regimen Development and Clinical Trial Design
Marjorie Imperial

EP-TBS-74-Leveraging Neural Networks and Imaging Experts in Loops for Automated Tuberculosis Screening Using Chest Radiographs in Population Screening Programs to ensure efficient workflows.
Amit Kharat

EP-TBS-75-A model for the integration of traditional medicine into conventional medicine for the treatment of Tuberculosis (TB) in Zimbabwe
Winnet Enerita Chipato

EP-TBS-76-Point-of-Care Saliva Assay for Levofloxacin Concentrations and Personalized Dosing in Patients with Multidrug-Resistant Tuberculosis in Tanzania
Sagal Mohamed

EP-TBS-77-PBPK Model Informed Prediction to Evaluate the Effect of Renal Impairment and OCT genotypes on the Ethambutol Disposition
Yumi Park

EP-TBS-78-Development of Population Pharmacokinetic Model of the First-line anti-TB drugs in Korean patients with TB for Therapeutic Drug Monitoring Guided Dose Adjustment
Yumi Park

EP-TBS-79-Model Informed Personalized Dosing Algorithm Development for TB Therapy in Center for Personalized Precision Medicine (cPMTb)
Yumi Park

EP-TBS-80-Classifying adherence trajectories: an innovative tool for regimen development
Stephanie Law

EP-TBS-81-Predicting pretomanid penetration into patient lesions of tuberculosis
Jacqueline Ernest

EP-TBS-82-Rifapentine pharmacokinetics and pharmacodynamics: murine and human models to identify optimal dosing for treatment of latent M. tuberculosis infection
Jacqueline Ernest

EP-TBS-83-SLCO1B1 and SLC10A1 polymorphism and plasma rifampin concentrations in patients with co-morbidity tuberculosis-diabetes mellitus in Baja California, Mexico
Ricardo Perea-Jacobo

EP-TBS-84-Individual-Level Data Meta-Analysis of Adverse Events from Clinical Trials of Drug Sensitive Tuberculosis Treatment Regimens
Leah Jarlsberg

EP-TBS-85-G-clamp-inspired ligands and their effects on G-quadruplexes from Mycobacterium tuberculosis
Egor Shitikov

EP-TBS-86-Prediction of early bacterial activity (EBA) of bedaquiline in tuberculosis
Federico Romano

Loading...
Channel 7
TBS2A-TB infection and disease - the details: plenary session
event_note
Loading...
query_builder 15:00 - 16:22 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel TBScience session
mic English
TBS2A-TB infection and disease - the details: plenary session
*Please scroll down for more information*
Recent research has suggested that M. tuberculosis can present as more subtle states than just 'latent' infection and active disease. This has relevant diagnostic, preventive, therapeutic, transmission, modelling and economic analyses implications. This session is intended to discuss different implications of the spectrum of tuberculosis infection.

15:00 - 15:03: Introductory note


15:03 - 15:23: Subclinical TB in epidemiological models: What we know, what we don't, and what difference it makes

Emily Kendall

15:23 - 15:43: Bacterial and host determinants of cough aerosol culture-positivity in patients with drug-resistant or drug-susceptible TB

Grant Theron

15:43 - 16:03: Natural history of subclinical tuberculosis tracked by PET/CT and blood biomarkers

Anna Coussens

16:03 - 16:22: Live Q&A


Loading...
Channel 7
TBS2B-Bacterial metabolic activity and the host response in TB disease: oral abstract presentations
event_note
Loading...
query_builder 16:30 - 17:12 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel TBScience session
mic English
TBS2B-Bacterial metabolic activity and the host response in TB disease: oral abstract presentations
*Please scroll down for more information*
Recent research has suggested that M. tuberculosis can present as more subtle states than just 'latent' infection and active disease. This has relevant diagnostic, preventive, therapeutic, transmission, modelling and economic analyses implications. This session is intended to discuss different implications of the spectrum of tuberculosis infection.

16:30 - 16:32: Session introduction


16:32 - 16:40: TBS-OA-05-Transcriptomic profile of aerosolized Mycobacterium tuberculosis from patients during the early phase of drug-sensitive anti-tuberculosis treatment

Ambreen Shaikh

16:40 - 16:48: TBS-OA-06-Antigen-specific T cell activation distinguishes between recent and remote tuberculosis infection

Elisa Nemes

16:48 - 16:56: TBS-OA-07-Self-clearance of Mycobacterium tuberculosis infection: implications for lifetime risk and population at-risk of tuberculosis disease

Jon C. Emery

16:56 - 17:04: TBS-OA-08-Cough-independent production of metabolically active Mycobacterium tuberculosis in bioaerosol

Benjamin Patterson

17:04 - 17:12: Live Q&A


Loading...
Channel 7
TBS2C-Dead or alive? Implications of spectrum of M. tuberculosis infection: round table
event_note
Loading...
query_builder 17:20 - 18:05 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel TBScience session
mic English
TBS2C-Dead or alive? Implications of spectrum of M. tuberculosis infection: round table
*Please scroll down for more information*
Recent research has suggested that M. tuberculosis can present as more subtle states than just 'latent' infection and active disease. This has relevant diagnostic, preventive, therapeutic, transmission, modelling and economic analyses implications. This session is intended to discuss different implications of the spectrum of tuberculosis infection.

17:20 - 17:45: Round table

Simone Joosten
Rein Houben
Paul Drain

17:45 - 18:05: Live Q&A

Simone Joosten
Rein Houben

Loading...
E-posters
EPTBS-TBScience 2020 - E-posters - Displayed All Conference Days
event_note
Loading...
query_builder 10:00 - 11:00 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel E-poster session
mic English
EPTBS-TBScience 2020 - E-posters - Displayed All Conference Days
*Please scroll down for more information*
All TBScience 2020 E-posters will be displayed from 10 am Central European Summer Time (CEST), on Wednesday, 21 October for the duration of the conference and beyond

EP-TBS-01-Increased neutrophil count and decreased neutrophil CD15 expression correlate with TB disease severity and treatment response
Lerato Ndlovu

EP-TBS-02-Genome-wide identification of Mycobacterium tuberculosis genetic markers associated with the history of BCG vaccination
Kamela Charmaine S. Ng

EP-TBS-03-Characterization of regulatory B-cells for tuberculosis management
Irene Latorre

EP-TBS-04-Different antimycobacterial activity of alveolar macrophages in various lung legions of tuberculosis patients
Sergey Skornyakov

EP-TBS-05-Plasma mediators of phagocytosis in tuberculosis patients during anti-TB treatment and zinc supplementation
Victory Edem

EP-TBS-06-Discerning divergent tuberculosis endotypes: A meta-analysis of individual patient data
Andrew DiNardo

EP-TBS-07-Plasma Interferon (IFN)-g Inducible Protein 10 (IP-10) levels but not the QuantiFERON Gold plus assay correlate with disease severity and paradoxical reactions in extrapulmonary tuberculosis
Isabelle Suarez

EP-TBS-08-Host immune factors related to non-multidrug resistant tuberculosis with treatment history in Vietnam
Naoto Keicho

EP-TBS-09-Risk factors for the development of tuberculosis in children with chronic non-specific lung diseases.
Sofya Nakonechnaya

EP-TBS-10-Polyfunctional T-cells and IL-2 production decrease during pregnancy in women with latent TB infection
Jyoti Mathad

EP-TBS-11-Neutrophils Contribute to Tuberculosis-linked Inflammation and lung pathology
Caleb Nwongbouwoh Muefong

EP-TBS-12-Association of neutrophil-derived inflammatory mediator levels with lung pathology in active tuberculosis at diagnosis
Caleb Nwongbouwoh Muefong

EP-TBS-13-Characterising the BCG-induced antibody response for antigen discovery
Rachel Tanner

EP-TBS-14-ESAT-6 / CFP-10-stimulated metabolic activity of pleural fluid cells if cured tuberculosis or TB / HIV
Sergey Skornyakov

EP-TBS-15-Blood-Based Biomarkers of Tuberculosis in Children Integrating Metabolomic and Transcriptomic Data
Jeffrey A Tornheim

EP-TBS-16-Identification of TGF-β1 in pleural tuberculosis: the possible role in fibrosis
Silvio Renan Pinheiro Victor de Araújo

EP-TBS-17-Analysis of serum microRNAs as pulmonary tuberculosis biomarkers
JaeIn Jung

EP-TBS-18-Up-regulated programmed death protein 1 expression on CD4 T cells in patients with MDR-TB  associated with lung lesion and mycobacterial load
Qi Tan

EP-TBS-19-Malnutrition affects levels of vascular endothelial growth factor levels among children and adolescents with pulmonary tuberculosis?
Caio Pluvier Duarte Costa

EP-TBS-20-Towards identification of protein markers of Mycobacterium tuberculosis H37Rv extracellular vesicles (EV)
MEHALENE JAYARAM

EP-TBS-21-Increased frequency of CD39+ regulatory T cells in the pleural fluid of patients with Tuberculosisin comparison to other exudative causes
Ana Paula Santos

EP-TBS-22-Longitudinal analysis of M. tuberculosis-specific T cell responses demonstrates dynamic T cell responses to ESAT-6 and CFP-10 during pregnancy independently of mitogen responses.
Aparajita Saha

EP-TBS-23-Serum Cytokine Profile as Biomarker for Multi-drug Resistant Tuberculosis
Alahaman Nana Boakye

EP-TBS-24-Reanalysis and validation of Tuberculosis genes signature in blood and pleural fluid from patients with exudative pleural effusion
Raquel da Silva Corrêa

EP-TBS-25-TimBre, Cough based screening of Pulmonary Tuberculosis using Machine Learning that is Explainable and Interpretable
Rahul Pathri

EP-TBS-26-HbA1C as prognostic factor in PTB
Sarang Patil

EP-TBS-27-Better intradermal delivery for bacille Calmette-Guérin (BCG) vaccine by microneedles in healthy adults of S. Korea
Hyejon Lee

EP-TBS-28-MULTIPLEX BIOMARKER ASSAY FOR DETECTION OF MYCOBACTERIUM TUBERCULOSIS
Puneet Gupta

EP-TBS-29-Role of the chemokine receptor CXCR3 in the recruitment and retention of lung resident memory T cells following a pulmonary TB vaccine. 
Warwick Britton

EP-TBS-31-Benefit of Quantiferon-TB Gold plus in incidence of TB disease in Heath care workers of Central Chest Institute of Thailand
piamlarp sangsayunh

EP-TBS-32-The blood monocyte/lymphocyte, neutrophil/lymphocyte and platelet/lymphocyte ratios in children with pulmonary tuberculosis
Larissa Gorbach

EP-TBS-33-Pulmonary tuberculosis patients have an anaerobe-enriched microbiota associated with a pro-inflammatory peripheral host immune phenotype
Charissa Naidoo

EP-TBS-34-The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on rifampicin resistant and multidrug resistant tuberculosis in India and China
Chathika Weerasuriya

EP-TBS-36-Novel, culture-free, same-day TB diagnosis with ultrasensitive ELISA
Rikiya Takeuchi

EP-TBS-37-Tuberculosis screening in point-of-care settings: Proof-of-concept for a fast and easy sample-to-answer qPCR-based protocol
Alexandre Dias Tavares Costa

EP-TBS-38-Diagnostic accuracy of three urine lipoarabinomannan tuberculosis assays in HIV-negative outpatients
Tobias Broger

EP-TBS-39-To Study The Presence Of Live Mycobacterium Tuberculosis In Resected Lung Specimens Of Patients Undergoing Lung resection Surgery For Post-Tuberculosis Sequelae
Pallavi Purwar

EP-TBS-40-What can tuberculosis prevalence surveys tell us about the duration of asymptomatic bacteriologically-positive disease?
Chu-Chang Ku

EP-TBS-41-An RNA signature for tuberculosis risk in pregnant women: a prospective cohort study from India
Jyoti Mathad

EP-TBS-42-Analysis of mycobacterial trans-renal DNA for the diagnosis of Tuberculous Meningitis in adults.
Manisha Dass

EP-TBS-43-Developing a tool to identify and screen Latent Tuberculosis Infection (LTBI) with likelihood of progression to active Tuberculosis (ATB)
Prashant Singh

EP-TBS-44-QuantiFERON TB plus-negative results in clinically diagnosed paediatric tuberculosis: immune suppression or misdiagnosis?
Gloria Ivy Mensah

EP-TBS-45-Evaluation of a blood-based antigen test for tuberculosis in HIV-exposed children younger than 5 years
Tony Hu

EP-TBS-46-Adverse drug reactions in MDR TB Patients on ATT
Sarang Patil

EP-TBS-47-Species and Drug Susceptibility profile of Non-tuberculous Mycobacteria isolated from presumptive TB cases
PRIYA RAJENDRAN

EP-TBS-48-MAMA-PCR assay for the detection of point mutations associated with drug resistance in Mycobacterium tuberculosis clinical isolates
Raquel Muñiz-Salazar

EP-TBS-49-Genomic diversity in Mycobacterium tuberculosis from human lung resections reveals a high degree of multiclonal infections in a high-burden MDR-TB setting
Miguel Moreno-Molina

EP-TBS-50-Pathogen genome sequencing to guide treatment regimen designs for multidrug-resistant tuberculosis
Hans-Peter Grobbel

EP-TBS-51-An evolutionary functional genomics approach identifies novel candidate regions involved in isoniazid resistance in Mycobacterium tuberculosis
Victoria Furió

EP-TBS-52-Antibiotic Resistance Profile Determination Using Whole Genome Sequencing
Ryan Howard

EP-TBS-53-Rapid genomic drug resistance prediction from clinical Mycobacterium tuberculosis specimens using amplicon based deep sequencing based on Deeplex-MycTB
Stefan Niemann

EP-TBS-54-Multi-resistant tuberculosis and HIV infection in Kinshasa: 2011-2018. DRC “Epidemiological, clinical and therapeutic aspects”
Nicole ANSHAMBI

EP-TBS-55-Long Read DNA Sequencing of XDR/MDR Tuberculosis Samples to Investigate Factors Leading to Resistance and Virulence
Michael Harris

EP-TBS-56-Genome-wide detection of epistasis in antibiotic resistant M. tuberculosis
Anna Green

EP-TBS-57-Population structure, biogeography and transmissibility of Mycobacterium tuberculosis
Luca Freschi

EP-TBS-58-Safety and Efficacy of an MDR-TB All-oral Short-course Regimen in China: An Preliminary Analysis of the MDR-Chi clinical trial
Liang Fu

EP-TBS-59-Drug exposure and minimum inhibitory concentration predict pulmonary tuberculosis treatment response
Xubin Zheng

EP-TBS-60-A novel therapeutic vaccine against multi-drug resistant tuberculosis by T cell-immunity in phase 1 clinical trial.
Masaji Okada

EP-TBS-61-Improving the safety of TB therapy with novel diagnostic biomarkers of liver toxicity – a study in UK and Ugandan patients
Derek Sloan

EP-TBS-62-Tuberculosis meningitis mouse model
Tuhina Gupta

EP-TBS-63-Pharmacokinetics of the three-drug fixed-dose dispersible tablet in children
Aziza Pakhlavonova

EP-TBS-64-Does BCG Vaccination protect against infection with Mycobacterium tuberculosis in Vietnamese schoolchildren?
Puck Pelzer

EP-TBS-65-Time to positivity as a surrogate biomarker of time to culture conversion
Belén P. Solans

EP-TBS-66-Use of the contact management register to identify those with Active and Latent TB, Kenya, Jan-March 2020
RHODA POLA

EP-TBS-67-Predicting Efficacy Outcome of Nine Tuberculosis Drugs in Phase 2a First-in-patients Studies
Nan Zhang

EP-TBS-69-Predicting optimal treatment durations for tuberculosis patients: a risk stratification algorithm and clinical simulation tool
Marjorie Imperial

EP-TBS-70-Adverse Drug Reactions in MDR TB Patients on Category IV Regimen in Western Odisha
SUMAN KUMAR JAGATY

EP-TBS-71-The effect of antiretroviral therapy and preventive tuberculosis therapy with anti-TB drugs on the duration of TB remission in HIV-infected patients
Igor Medvinskiy

EP-TBS-72-A Urine Colorimetric Assay for Levofloxacin Concentrations and Optimized Regimen Development
Prakruti Rao

EP-TBS-73-Development and Application of an Integrated Biomarker - Clinical Endpoint Tool for Late Stage TB Regimen Development and Clinical Trial Design
Marjorie Imperial

EP-TBS-74-Leveraging Neural Networks and Imaging Experts in Loops for Automated Tuberculosis Screening Using Chest Radiographs in Population Screening Programs to ensure efficient workflows.
Amit Kharat

EP-TBS-75-A model for the integration of traditional medicine into conventional medicine for the treatment of Tuberculosis (TB) in Zimbabwe
Winnet Enerita Chipato

EP-TBS-76-Point-of-Care Saliva Assay for Levofloxacin Concentrations and Personalized Dosing in Patients with Multidrug-Resistant Tuberculosis in Tanzania
Sagal Mohamed

EP-TBS-77-PBPK Model Informed Prediction to Evaluate the Effect of Renal Impairment and OCT genotypes on the Ethambutol Disposition
Yumi Park

EP-TBS-78-Development of Population Pharmacokinetic Model of the First-line anti-TB drugs in Korean patients with TB for Therapeutic Drug Monitoring Guided Dose Adjustment
Yumi Park

EP-TBS-79-Model Informed Personalized Dosing Algorithm Development for TB Therapy in Center for Personalized Precision Medicine (cPMTb)
Yumi Park

EP-TBS-80-Classifying adherence trajectories: an innovative tool for regimen development
Stephanie Law

EP-TBS-81-Predicting pretomanid penetration into patient lesions of tuberculosis
Jacqueline Ernest

EP-TBS-82-Rifapentine pharmacokinetics and pharmacodynamics: murine and human models to identify optimal dosing for treatment of latent M. tuberculosis infection
Jacqueline Ernest

EP-TBS-83-SLCO1B1 and SLC10A1 polymorphism and plasma rifampin concentrations in patients with co-morbidity tuberculosis-diabetes mellitus in Baja California, Mexico
Ricardo Perea-Jacobo

EP-TBS-84-Individual-Level Data Meta-Analysis of Adverse Events from Clinical Trials of Drug Sensitive Tuberculosis Treatment Regimens
Leah Jarlsberg

EP-TBS-85-G-clamp-inspired ligands and their effects on G-quadruplexes from Mycobacterium tuberculosis
Egor Shitikov

EP-TBS-86-Prediction of early bacterial activity (EBA) of bedaquiline in tuberculosis
Federico Romano

Loading...
Channel 7
TBS3A-What is new in drug-resistance detection: plenary session
event_note
Loading...
query_builder 15:00 - 16:22 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel TBScience session
mic English
TBS3A-What is new in drug-resistance detection: plenary session
*Please scroll down for more information*
Multiple active anti-mycobaterial drugs are required to cure tuberculosis. Monotherapy or treatment with insufficient active drugs accelerates the development of mycobacterial resistance resulting in treatment failures and, ultimately, undermining elimination strategies. For this reason, understanding the detailed mechanisms of resistance, as well as interactions between the host and different drugs, is important as it allows in vivo activity to be predicted. This session aims to discuss recent findings with respect to our understanding of anti-mycobacterial drug resistance and the prediction of susceptibility, notably based on genome sequence data.

15:00 - 15:03: Introductory note


15:03 - 15:23: Sequencing to support DR TB treatment decisions: a new landscape of options

Timothy Rodwell

15:23 - 15:43: From MoR to MoA to new drugs

Thomas Dick

15:43 - 16:03: The role of M. tuberculosis within-host heterogeneity. Can it inform TB patient care?

Maha Farhat

16:03 - 16:22: Live Q&A


Loading...
Channel 7
TBS3B-Latest research in drug resistance detection, mechanism and treatments: oral abstract presentations
event_note
Loading...
query_builder 16:30 - 17:12 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel TBScience session
mic English
TBS3B-Latest research in drug resistance detection, mechanism and treatments: oral abstract presentations
*Please scroll down for more information*
Multiple active anti-mycobaterial drugs are required to cure tuberculosis. Monotherapy or treatment with insufficient active drugs accelerates the development of mycobacterial resistance resulting in treatment failures and ultimately undermines elimination strategies. For this reason, understanding the detailed mechanisms of resistance as well as interactions between the host and different drugs is important as it allows in vivo activity to be predicted. This session aims to discuss recent findings with respect to our understanding of anti-mycobacterial drug resistance and the prediction of susceptibility notably based on genome sequence data.

16:30 - 16:32: Session introduction


16:32 - 16:40: TBS-OA-09-Association of delamanid concentrations with treatment outcomes or drug resistance among patients with MDR-TB.

Daniel S. Graciaa

16:40 - 16:48: TBS-OA-10-High frequency of bedaquiline resistance in programmatically treated drug-resistant TB patients with sustained culture-positivity in Cape Town, South Africa

Brigitta Derendinger

16:48 - 16:56: TBS-OA-11-ncRv0842c, a smallRNA regulating the efflux pump Rv0842 involved in rifampicin tolerance in M. tuberculosis

Paolo Miotto

16:56 - 17:04: TBS-OA-12-Genomic sequence characteristics and the empirical accuracy of short-read sequencing in Mycobacterium tuberculosis

Maximillian Marin

17:04 - 17:12: Live Q&A


Loading...
Channel 7
TBS3C-The detection of genetic variants associated with antibiotic tolerance, persistence and drug resistance: panel discussion
event_note
Loading...
query_builder 17:20 - 18:05 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel TBScience session
mic English
TBS3C-The detection of genetic variants associated with antibiotic tolerance, persistence and drug resistance: panel discussion
*Please scroll down for more information*
Multiple active anti-mycobaterial drugs are required to cure tuberculosis. Monotherapy or treatment with insufficient active drugs accelerates the development of mycobacterial resistance resulting in treatment failures and, ultimately, undermining elimination strategies. For this reason, understanding the detailed mechanisms of resistance, as well as interactions between the host and different drugs, is important as it allows in vivo activity to be predicted. This session aims to discuss recent findings with respect to our understanding of anti-mycobacterial drug resistance and the prediction of susceptibility, notably based on genome sequence data.

17:20 - 17:45: Panel discussion

Maha Farhat
Thomas Dick
Sarah Fortune
Timothy Rodwell

17:45 - 18:05: Live Q&A

Maha Farhat
Thomas Dick
Sarah Fortune
Timothy Rodwell

Loading...
E-posters
EPTBS-TBScience 2020 - E-posters - Displayed All Conference Days
event_note
Loading...
query_builder 10:00 - 11:00 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel E-poster session
mic English
EPTBS-TBScience 2020 - E-posters - Displayed All Conference Days
*Please scroll down for more information*
All TBScience 2020 E-posters will be displayed from 10 am Central European Summer Time (CEST), on Wednesday, 21 October for the duration of the conference and beyond

EP-TBS-01-Increased neutrophil count and decreased neutrophil CD15 expression correlate with TB disease severity and treatment response
Lerato Ndlovu

EP-TBS-02-Genome-wide identification of Mycobacterium tuberculosis genetic markers associated with the history of BCG vaccination
Kamela Charmaine S. Ng

EP-TBS-03-Characterization of regulatory B-cells for tuberculosis management
Irene Latorre

EP-TBS-04-Different antimycobacterial activity of alveolar macrophages in various lung legions of tuberculosis patients
Sergey Skornyakov

EP-TBS-05-Plasma mediators of phagocytosis in tuberculosis patients during anti-TB treatment and zinc supplementation
Victory Edem

EP-TBS-06-Discerning divergent tuberculosis endotypes: A meta-analysis of individual patient data
Andrew DiNardo

EP-TBS-07-Plasma Interferon (IFN)-g Inducible Protein 10 (IP-10) levels but not the QuantiFERON Gold plus assay correlate with disease severity and paradoxical reactions in extrapulmonary tuberculosis
Isabelle Suarez

EP-TBS-08-Host immune factors related to non-multidrug resistant tuberculosis with treatment history in Vietnam
Naoto Keicho

EP-TBS-09-Risk factors for the development of tuberculosis in children with chronic non-specific lung diseases.
Sofya Nakonechnaya

EP-TBS-10-Polyfunctional T-cells and IL-2 production decrease during pregnancy in women with latent TB infection
Jyoti Mathad

EP-TBS-11-Neutrophils Contribute to Tuberculosis-linked Inflammation and lung pathology
Caleb Nwongbouwoh Muefong

EP-TBS-12-Association of neutrophil-derived inflammatory mediator levels with lung pathology in active tuberculosis at diagnosis
Caleb Nwongbouwoh Muefong

EP-TBS-13-Characterising the BCG-induced antibody response for antigen discovery
Rachel Tanner

EP-TBS-14-ESAT-6 / CFP-10-stimulated metabolic activity of pleural fluid cells if cured tuberculosis or TB / HIV
Sergey Skornyakov

EP-TBS-15-Blood-Based Biomarkers of Tuberculosis in Children Integrating Metabolomic and Transcriptomic Data
Jeffrey A Tornheim

EP-TBS-16-Identification of TGF-β1 in pleural tuberculosis: the possible role in fibrosis
Silvio Renan Pinheiro Victor de Araújo

EP-TBS-17-Analysis of serum microRNAs as pulmonary tuberculosis biomarkers
JaeIn Jung

EP-TBS-18-Up-regulated programmed death protein 1 expression on CD4 T cells in patients with MDR-TB  associated with lung lesion and mycobacterial load
Qi Tan

EP-TBS-19-Malnutrition affects levels of vascular endothelial growth factor levels among children and adolescents with pulmonary tuberculosis?
Caio Pluvier Duarte Costa

EP-TBS-20-Towards identification of protein markers of Mycobacterium tuberculosis H37Rv extracellular vesicles (EV)
MEHALENE JAYARAM

EP-TBS-21-Increased frequency of CD39+ regulatory T cells in the pleural fluid of patients with Tuberculosisin comparison to other exudative causes
Ana Paula Santos

EP-TBS-22-Longitudinal analysis of M. tuberculosis-specific T cell responses demonstrates dynamic T cell responses to ESAT-6 and CFP-10 during pregnancy independently of mitogen responses.
Aparajita Saha

EP-TBS-23-Serum Cytokine Profile as Biomarker for Multi-drug Resistant Tuberculosis
Alahaman Nana Boakye

EP-TBS-24-Reanalysis and validation of Tuberculosis genes signature in blood and pleural fluid from patients with exudative pleural effusion
Raquel da Silva Corrêa

EP-TBS-25-TimBre, Cough based screening of Pulmonary Tuberculosis using Machine Learning that is Explainable and Interpretable
Rahul Pathri

EP-TBS-26-HbA1C as prognostic factor in PTB
Sarang Patil

EP-TBS-27-Better intradermal delivery for bacille Calmette-Guérin (BCG) vaccine by microneedles in healthy adults of S. Korea
Hyejon Lee

EP-TBS-28-MULTIPLEX BIOMARKER ASSAY FOR DETECTION OF MYCOBACTERIUM TUBERCULOSIS
Puneet Gupta

EP-TBS-29-Role of the chemokine receptor CXCR3 in the recruitment and retention of lung resident memory T cells following a pulmonary TB vaccine. 
Warwick Britton

EP-TBS-31-Benefit of Quantiferon-TB Gold plus in incidence of TB disease in Heath care workers of Central Chest Institute of Thailand
piamlarp sangsayunh

EP-TBS-32-The blood monocyte/lymphocyte, neutrophil/lymphocyte and platelet/lymphocyte ratios in children with pulmonary tuberculosis
Larissa Gorbach

EP-TBS-33-Pulmonary tuberculosis patients have an anaerobe-enriched microbiota associated with a pro-inflammatory peripheral host immune phenotype
Charissa Naidoo

EP-TBS-34-The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on rifampicin resistant and multidrug resistant tuberculosis in India and China
Chathika Weerasuriya

EP-TBS-36-Novel, culture-free, same-day TB diagnosis with ultrasensitive ELISA
Rikiya Takeuchi

EP-TBS-37-Tuberculosis screening in point-of-care settings: Proof-of-concept for a fast and easy sample-to-answer qPCR-based protocol
Alexandre Dias Tavares Costa

EP-TBS-38-Diagnostic accuracy of three urine lipoarabinomannan tuberculosis assays in HIV-negative outpatients
Tobias Broger

EP-TBS-39-To Study The Presence Of Live Mycobacterium Tuberculosis In Resected Lung Specimens Of Patients Undergoing Lung resection Surgery For Post-Tuberculosis Sequelae
Pallavi Purwar

EP-TBS-40-What can tuberculosis prevalence surveys tell us about the duration of asymptomatic bacteriologically-positive disease?
Chu-Chang Ku

EP-TBS-41-An RNA signature for tuberculosis risk in pregnant women: a prospective cohort study from India
Jyoti Mathad

EP-TBS-42-Analysis of mycobacterial trans-renal DNA for the diagnosis of Tuberculous Meningitis in adults.
Manisha Dass

EP-TBS-43-Developing a tool to identify and screen Latent Tuberculosis Infection (LTBI) with likelihood of progression to active Tuberculosis (ATB)
Prashant Singh

EP-TBS-44-QuantiFERON TB plus-negative results in clinically diagnosed paediatric tuberculosis: immune suppression or misdiagnosis?
Gloria Ivy Mensah

EP-TBS-45-Evaluation of a blood-based antigen test for tuberculosis in HIV-exposed children younger than 5 years
Tony Hu

EP-TBS-46-Adverse drug reactions in MDR TB Patients on ATT
Sarang Patil

EP-TBS-47-Species and Drug Susceptibility profile of Non-tuberculous Mycobacteria isolated from presumptive TB cases
PRIYA RAJENDRAN

EP-TBS-48-MAMA-PCR assay for the detection of point mutations associated with drug resistance in Mycobacterium tuberculosis clinical isolates
Raquel Muñiz-Salazar

EP-TBS-49-Genomic diversity in Mycobacterium tuberculosis from human lung resections reveals a high degree of multiclonal infections in a high-burden MDR-TB setting
Miguel Moreno-Molina

EP-TBS-50-Pathogen genome sequencing to guide treatment regimen designs for multidrug-resistant tuberculosis
Hans-Peter Grobbel

EP-TBS-51-An evolutionary functional genomics approach identifies novel candidate regions involved in isoniazid resistance in Mycobacterium tuberculosis
Victoria Furió

EP-TBS-52-Antibiotic Resistance Profile Determination Using Whole Genome Sequencing
Ryan Howard

EP-TBS-53-Rapid genomic drug resistance prediction from clinical Mycobacterium tuberculosis specimens using amplicon based deep sequencing based on Deeplex-MycTB
Stefan Niemann

EP-TBS-54-Multi-resistant tuberculosis and HIV infection in Kinshasa: 2011-2018. DRC “Epidemiological, clinical and therapeutic aspects”
Nicole ANSHAMBI

EP-TBS-55-Long Read DNA Sequencing of XDR/MDR Tuberculosis Samples to Investigate Factors Leading to Resistance and Virulence
Michael Harris

EP-TBS-56-Genome-wide detection of epistasis in antibiotic resistant M. tuberculosis
Anna Green

EP-TBS-57-Population structure, biogeography and transmissibility of Mycobacterium tuberculosis
Luca Freschi

EP-TBS-58-Safety and Efficacy of an MDR-TB All-oral Short-course Regimen in China: An Preliminary Analysis of the MDR-Chi clinical trial
Liang Fu

EP-TBS-59-Drug exposure and minimum inhibitory concentration predict pulmonary tuberculosis treatment response
Xubin Zheng

EP-TBS-60-A novel therapeutic vaccine against multi-drug resistant tuberculosis by T cell-immunity in phase 1 clinical trial.
Masaji Okada

EP-TBS-61-Improving the safety of TB therapy with novel diagnostic biomarkers of liver toxicity – a study in UK and Ugandan patients
Derek Sloan

EP-TBS-62-Tuberculosis meningitis mouse model
Tuhina Gupta

EP-TBS-63-Pharmacokinetics of the three-drug fixed-dose dispersible tablet in children
Aziza Pakhlavonova

EP-TBS-64-Does BCG Vaccination protect against infection with Mycobacterium tuberculosis in Vietnamese schoolchildren?
Puck Pelzer

EP-TBS-65-Time to positivity as a surrogate biomarker of time to culture conversion
Belén P. Solans

EP-TBS-66-Use of the contact management register to identify those with Active and Latent TB, Kenya, Jan-March 2020
RHODA POLA

EP-TBS-67-Predicting Efficacy Outcome of Nine Tuberculosis Drugs in Phase 2a First-in-patients Studies
Nan Zhang

EP-TBS-69-Predicting optimal treatment durations for tuberculosis patients: a risk stratification algorithm and clinical simulation tool
Marjorie Imperial

EP-TBS-70-Adverse Drug Reactions in MDR TB Patients on Category IV Regimen in Western Odisha
SUMAN KUMAR JAGATY

EP-TBS-71-The effect of antiretroviral therapy and preventive tuberculosis therapy with anti-TB drugs on the duration of TB remission in HIV-infected patients
Igor Medvinskiy

EP-TBS-72-A Urine Colorimetric Assay for Levofloxacin Concentrations and Optimized Regimen Development
Prakruti Rao

EP-TBS-73-Development and Application of an Integrated Biomarker - Clinical Endpoint Tool for Late Stage TB Regimen Development and Clinical Trial Design
Marjorie Imperial

EP-TBS-74-Leveraging Neural Networks and Imaging Experts in Loops for Automated Tuberculosis Screening Using Chest Radiographs in Population Screening Programs to ensure efficient workflows.
Amit Kharat

EP-TBS-75-A model for the integration of traditional medicine into conventional medicine for the treatment of Tuberculosis (TB) in Zimbabwe
Winnet Enerita Chipato

EP-TBS-76-Point-of-Care Saliva Assay for Levofloxacin Concentrations and Personalized Dosing in Patients with Multidrug-Resistant Tuberculosis in Tanzania
Sagal Mohamed

EP-TBS-77-PBPK Model Informed Prediction to Evaluate the Effect of Renal Impairment and OCT genotypes on the Ethambutol Disposition
Yumi Park

EP-TBS-78-Development of Population Pharmacokinetic Model of the First-line anti-TB drugs in Korean patients with TB for Therapeutic Drug Monitoring Guided Dose Adjustment
Yumi Park

EP-TBS-79-Model Informed Personalized Dosing Algorithm Development for TB Therapy in Center for Personalized Precision Medicine (cPMTb)
Yumi Park

EP-TBS-80-Classifying adherence trajectories: an innovative tool for regimen development
Stephanie Law

EP-TBS-81-Predicting pretomanid penetration into patient lesions of tuberculosis
Jacqueline Ernest

EP-TBS-82-Rifapentine pharmacokinetics and pharmacodynamics: murine and human models to identify optimal dosing for treatment of latent M. tuberculosis infection
Jacqueline Ernest

EP-TBS-83-SLCO1B1 and SLC10A1 polymorphism and plasma rifampin concentrations in patients with co-morbidity tuberculosis-diabetes mellitus in Baja California, Mexico
Ricardo Perea-Jacobo

EP-TBS-84-Individual-Level Data Meta-Analysis of Adverse Events from Clinical Trials of Drug Sensitive Tuberculosis Treatment Regimens
Leah Jarlsberg

EP-TBS-85-G-clamp-inspired ligands and their effects on G-quadruplexes from Mycobacterium tuberculosis
Egor Shitikov

EP-TBS-86-Prediction of early bacterial activity (EBA) of bedaquiline in tuberculosis
Federico Romano

Loading...
Channel 7
TBS4A-Innovations in TB therapeutics: plenary session
event_note
Loading...
query_builder 15:00 - 16:22 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel TBScience session
mic English
TBS4A-Innovations in TB therapeutics: plenary session
*Please scroll down for more information*
Tuberculosis (TB) therapeutics research is experiencing a renaissance with an increasing number of new compounds, innovative tools and strategies undergoing evaluation as part of novel regimen development. This is welcome progress as the field seeks to address the long durations of treatment, toxicities, drug–drug interactions and high costs of current therapies. This session will highlight the potential of therapeutic vaccines, innovative tools for regimen development and genomic discoveries with relevance to development of host-directed therapies for curing TB.

15:00 - 15:03: Introductory note


15:03 - 15:23: Opportunities and risks: using therapeutic TB vaccines to improve cures and shorten treatment for active disease

Gavin Churchyard

15:23 - 15:43: Single-bacilli response to drug exposure within lesional microenvironments: bug-drug interactions within the granuloma and beyond

Joshua Vasquez

15:43 - 16:03: Diversity of Mycobacterium tuberculosis and clinical outcomes of TB. The challenges posed for optimising HDT for TB

Margarida Saraiva

16:03 - 16:22: Live Q&A


Loading...
Channel 7
TBS4B-Innovations in TB therapeutics: oral abstract presentations
event_note
Loading...
query_builder 16:30 - 17:12 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel TBScience session
mic English
TBS4B-Innovations in TB therapeutics: oral abstract presentations
*Please scroll down for more information*
Tuberculosis (TB) therapeutics research is experiencing a renaissance with an increasing number of new compounds, innovative tools and strategies undergoing evaluation as part of novel regimen development. This is welcome progress as the field seeks to address the long durations of treatment, toxicities, drug–drug interactions and high costs of current therapies. This session will highlight the potential of therapeutic vaccines, innovative tools for regimen development and genomic discoveries with relevance to development of host-directed therapies for curing TB.

16:30 - 16:32: Session introduction


16:32 - 16:40: TBS-OA-13-An empirical modeling approach for regimen development: How to build a winning team.

Natasha Strydom

16:40 - 16:48: TBS-OA-14-The role of respiratory microbiome in early bactericidal activity of anti-tuberculosis therapy and treatment outcome

Wilber Sabiiti

16:48 - 16:56: TBS-OA-15-In silico assessment of adaptive trial design for TB regimen development

Vincent Chang

16:56 - 17:04: TBS-OA-16-Translational platform for predicting clinical outcomes for new combination regimens using pre-clinical and phase I data

Qianwen Wang

17:04 - 17:12: Live Q&A


Loading...
Channel 7
TBS4C-Innovations in TB therapeutics: panel discussion
event_note
Loading...
query_builder 17:20 - 18:05 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel TBScience session
mic English
TBS4C-Innovations in TB therapeutics: panel discussion
*Please scroll down for more information*
Tuberculosis (TB) therapeutics research is experiencing a renaissance with an increasing number of new compounds, innovative tools and strategies undergoing evaluation as part of novel regimen development. This is welcome progress as the field seeks to address the long durations of treatment, toxicities, drug–drug interactions and high costs of current therapies. This session will highlight the potential of therapeutic vaccines, innovative tools for regimen development and genomic discoveries with relevance to development of host-directed therapies for curing TB.

17:20 - 17:30: Panel discussion

Gavin Churchyard
Joshua Vasquez
Margarida Saraiva
Amina Jindani
Rada Savic

17:30 - 17:40: Live Q&A

Gavin Churchyard
Joshua Vasquez
Margarida Saraiva
Amina Jindani
Rada Savic

Loading...
Processing. Please wait.
Loading...